H.C. Wainwright lifts Vertex Pharmaceuticals Incorporated [VRTX] price estimate. Who else is bullish?

Vertex Pharmaceuticals Incorporated [NASDAQ: VRTX] loss -20.70% on the last trading session, reaching $215.28 price per share at the time. The company report on October 15, 2020 that Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency.

– Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data -.

– Phase 2 study of VX-864 continues to enroll and dose patients; data expected in H1 2021 -.

Vertex Pharmaceuticals Incorporated represents 260.47 million in outstanding shares, while the company has a total market value of $55.78 billion with the latest information. VRTX stock price has been found in the range of $213.1701 to $232.46.

If compared to the average trading volume of 1.23M shares, VRTX reached a trading volume of 17464019 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Vertex Pharmaceuticals Incorporated [VRTX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRTX shares is $306.91 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRTX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Vertex Pharmaceuticals Incorporated shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 31, 2020. The new note on the price target was released on July 08, 2020, representing the official price target for Vertex Pharmaceuticals Incorporated stock. Previously, the target price had yet another raise from $270 to $295, while H.C. Wainwright kept a Buy rating on VRTX stock. On April 28, 2020, analysts increased their price target for VRTX shares from 250 to 260.

The Average True Range (ATR) for Vertex Pharmaceuticals Incorporated is set at 10.92, with the Price to Sales ratio for VRTX stock in the period of the last 12 months amounting to 10.32. The Price to Book ratio for the last quarter was 7.43, with the Price to Cash per share for the same quarter was set at 21.04. Price to Free Cash Flow for VRTX in the course of the last twelve months was 21.82 with Quick ratio for the last quarter at 3.60.

Trading performance analysis for VRTX stock

Vertex Pharmaceuticals Incorporated [VRTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -19.83. With this latest performance, VRTX shares dropped by -19.54% in over the last four-week period, additionally sinking by -20.40% over the last 6 months – not to mention a rise of 22.26% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRTX stock in for the last two-week period is set at 25.57, with the RSI for the last a single of trading hit 19.65, and the three-weeks RSI is set at 29.96 for Vertex Pharmaceuticals Incorporated [VRTX]. The present Moving Average for the last 50 days of trading for this stock 267.60, while it was recorded at 261.48 for the last single week of trading, and 259.33 for the last 200 days.

Vertex Pharmaceuticals Incorporated [VRTX]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Vertex Pharmaceuticals Incorporated [VRTX] shares currently have an operating margin of +28.31 and a Gross Margin at +86.74. Vertex Pharmaceuticals Incorporated’s Net Margin is presently recorded at +28.49.

Return on Total Capital for VRTX is now 19.85, given the latest momentum, and Return on Invested Capital for the company is 20.07. Return on Equity for this stock inclined to 22.37, with Return on Assets sitting at 16.16. When it comes to the capital structure of this company, Vertex Pharmaceuticals Incorporated [VRTX] has a Total Debt to Total Equity ratio set at 11.06. Additionally, VRTX Total Debt to Total Capital is recorded at 9.96, with Total Debt to Total Assets ending up at 8.09. Long-Term Debt to Equity for the company is recorded at 10.24, with the Long-Term Debt to Total Capital now at 9.22.

Reflecting on the efficiency of the workforce at the company, Vertex Pharmaceuticals Incorporated [VRTX] managed to generate an average of $392,270 per employee. Receivables Turnover for the company is 7.88 with a Total Asset Turnover recorded at a value of 0.57.Vertex Pharmaceuticals Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.60 and a Current Ratio set at 3.70.

Vertex Pharmaceuticals Incorporated [VRTX]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Vertex Pharmaceuticals Incorporated posted 1.23/share EPS, while the average EPS was predicted by analysts to be reported at 1.15/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VRTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Vertex Pharmaceuticals Incorporated go to 25.19%.

An analysis of insider ownership at Vertex Pharmaceuticals Incorporated [VRTX]

There are presently around $52,308 million, or 96.00% of VRTX stock, in the hands of institutional investors. The top three institutional holders of VRTX stocks are: BLACKROCK INC. with ownership of 25,507,898, which is approximately 14.252% of the company’s market cap and around 0.10% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 21,198,502 shares of the stock with an approximate value of $4.56 billion in VRTX stocks shares; and VANGUARD GROUP INC, currently with $4.49 billion in VRTX stock with ownership of nearly 1.282% of the company’s market capitalization.

Positions in Vertex Pharmaceuticals Incorporated stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 554 institutional holders increased their position in Vertex Pharmaceuticals Incorporated [NASDAQ:VRTX] by around 15,115,245 shares. Additionally, 344 investors decreased positions by around 17,891,713 shares, while 113 investors held positions by with 209,968,878 shares. The mentioned changes placed institutional holdings at 242,975,836 shares, according to the latest SEC report filing. VRTX stock had 156 new institutional investments in for a total of 1,112,716 shares, while 65 institutional investors sold positions of 1,041,938 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam